Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Pharma
Gilead, Merck phase 3 data back first weekly HIV pill
Detailed phase 3 ISLEND-1 results show zero virologic failures for Gilead and Merck's ISL/LEN as potentially the first weekly HIV pill.
Angus Liu
Jul 21, 2026 10:00am
Gilead gets wild in bronze-winning Cannes spot
Jul 16, 2026 9:18am
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC
Jun 24, 2026 5:00pm
Fierce Biotech
Mapp, Gilead antivirals to be deployed in DRC Ebola trial: WHO
Jun 24, 2026 3:03pm
Novartis’ ‘Relax Your Tight End’ wins Cannes Pharma Grand Prix
Jun 23, 2026 9:06am
Merck-Gilead first-of-its-kind combo pill scores in 2 HIV trials
Jun 9, 2026 11:20am
